Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Sindrom koroner akut (SKA) merupakan masalah kesehatan nasional karena tingginya angka morbiditas dan mortalitas serta beban biaya yang dibutuhkan. Intervensi koroner perkutan (IKP) dan terapi antiplatelet seperti klopidogrel merupakan tata laksana yang direkomendasikan oleh organisasi kardiologi internasional. Meskipun demikian, pasien SKA masih dapat mengalami kejadian kardiovaskular mayor (KKM). Kemungkinan, resistensi klopidogrel berperan pada KKM sedangkan resistensi klopidogrel mungkin dipengaruhi oleh faktor genetik dan epigenetik. Penelitian ini bertujuan untuk mengetahui hubungan faktor genetik yaitu polimorfisme gen CYP2C19 dan P2Y12, serta epigenetik yaitu metilasi DNA gen CYP2C19 dan P2Y12 serta ekspresi miRNA-26a dengan resistensi klopidogrel dan pengaruhnya terhadap KKM pada pasien SKA pasca IKP. Untuk menganalisis hubungan faktor genetik dan epigenetik dengan resistensi klopidogrel, penelitian dilakukan dengan desain potong lintang, sedangkan untuk analisis hubungan faktor genetik dan epigenetik dengan KKM dilakukan dengan desain kohort prospektif. Subjek penelitian meliputi 201 pasien SKA pasca IKP dan mendapat terapi klopidogrel di Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita dari bulan September 2018 sampai dengan Juni 2020. Resistensi klopidogrel ditentukan dengan pemeriksaan light transmission aggregometry (LTA) apabila hasilnya lebih besar dari 59% dengan agonis ADP 20 mM. Deteksi polimorfisme gen CYP2C19 dan P2Y12 serta ekspresi miRNA-26a dilakukan dengan metode qRT-PCR, sedangkan metilasi DNA gen CYP2C19 dan P2Y12 dikerjakan dengan metode konversi bisulfit. Pasien diobservasi selama satu tahun dan jika ada angina pektoris, infark miokard akut (IMA) rekuren, stroke, atau kematian, dicatat sebagai KKM. Dari 201 subjek, terdapat 45,8% carrier mutant polimorfisme *2 dan *3 gen CYP2C19, 36,8% carrier mutant polimorfisme rs3679479 gen P2Y12, 10% hipometilasi DNA gen P2Y12, 80,1% hipometilasi DNA gen CYP2C19, dan 66,2% ekspresi miRNA-26a up regulated. Proporsi resisten klopidogrel adalah 49,8% dan proporsi KKM adalah 14,9% (kematian 7,5%). Terdapat hubungan antara merokok (p = 0,001; OR 0,37 [IK 95%; 0,20–0,68]), hipometilasi DNA gen CYP2C19 (p = 0,037; OR 2,13 [IK 95%; 1,04–4,37]), dan ekspresi miRNA-26a up regulated (p = 0,020; OR 2,03 [IK 95%; 1,12–3,68]) dengan resistensi klopidogrel. Terdapat hubungan antara jenis kelamin perempuan (p = 0,040; HR 2,73 [IK 95%; 1,05–7,14]), usia ≥ 60 tahun (p = 0,035; HR 2,17 [IK 95%; 1,06–4,48]), eGFR rendah (p = 0,001; HR 3,29 [IK 95%; 1,59–6,84]), dan polimorfisme *2 dan *3 gen CYP2C19 (p = 0,047; HR 2,12 [IK 95%; 1,01–4,46]) dengan KKM dalam satu tahun. Hanya faktor epigenetik berupa metilasi DNA gen CYP2C19 dan ekspresi miRNA-26a yang berhubungan dengan resistensi klopidogrel. Walaupun resistensi klopidogrel tidak berhubungan dengan KKM, terdapat hubungan antara faktor genetik polimorfisme *2 dan *3 gen CYP2C19 dengan KKM. ......Acute coronary syndrome (ACS) is a national health problem due to high morbidity and mortality, and cost burden as well. Percutaneous coronary intervention (PCI) and antiplatelet therapy such as clopidogrel are recommended. However, ACS patients could still experience major adverse cardiovascular events (MACE). Clopidogrel resistance possibly plays a role in MACE whereas it may be affected by genetic and epigenetic factors. Therefore, the objective of this study was to determine the relationship between genetic factors which are CYP2C19 and P2Y12 polymorphisms, as well as epigenetic factors which are DNA methylation of CYP2C19 and P2Y12, and miRNA-26a expression and their effects on MACE in post-PCI patients. To analyze the association between genetic and epigenetic factors and clopidogrel resistance, the study design was cross-sectional, while the study design of relationship between genetic and epigenetic factors and MACE was prospective cohort. The subjects were 201 post-PCI ACS patients who received clopidogrel therapy at Harapan Kita Hospital from September 2018 to June 2020. Clopidogrel resistance was determined by light transmission aggregometry (LTA) if the result was greater than 59% with agonist ADP 20 µM. The detection of CYP2C19 and P2Y12 gene polymorphisms and miRNA-26a expression were carried out by qRT-PCR method, while the DNA methylation of the CYP2C19 and P2Y12 genes were carried out by bisulfite conversion method. Patients were observed for one year and angina pectoris, recurrent acute myocardial infarction (AMI), stroke, or death, were recorded as MACE. From 201 subjects, 45.8% were CYP2C19*2 and CYP2C19*3 polymorphism mutant carrier, 36.8% were rs3679479 P2Y12 polymorphism mutant carrier, 10% were hypomethylated of P2Y12, 80.1% were hypomethylated of CYP2C19, and 66.2% were up regulated in miRNA-26a expression. 49.8% of subjects were clopidogrel resistant and 14.9% of subjects experienced MACE (death was 7.5%). Smoking (p = 0.001; OR 0.37 [CI 95%; 0.20–0.68]), hypomethylated of CYP2C19 (p = 0.037; OR 2.13 [CI 95%; 1.04–4.37]), and up regulated miRNA-26a expression (p = 0.020; OR 2.03 [CI 95%; 1.12–3.68]) were associated with clopidogrel resistance. Female gender (p = 0.040; HR 2.73 [CI 95%; 1.05–7.14]), age over 60 years old (p = 0.035; HR 2.17 [CI 95%; 1.06–4.48]), low eGFR (p = 0.001; HR 3.29 [CI 95%; 1.59–6.84]), and CYP2C19*2 and CYP2C19*3 polymorphisms (p = 0.047; HR 2.12 [CI 95%; 1.01–4.46]) were associated with MACE in one year. Only DNA methylation of CYP2C19 and miRNA-26a expression were associated with clopidogrel resistance. Although clopidogrel resistance was not associated with MACE, there was association between CYP2C19*2 and CYP2C19*3 polymorphisms and MACE.

Abstrak :
Latar Belakang Intervensi koroner perkuten primer (IKPP) merupakan sebuah skema tatalaksana yang bertujuan untuk mengembalikan suplai darah ke jantung pada pasien infark miokard dengan onset gejala di bawah 12 jam dan syok kardiogenik berat serta pasien dengan kontraindikasi terapi fibrinolitik.1 Saat ini, drug-eluting stent (DES) merupakan jenis stent yang direkomendasikan karena memiliki benefit lebih besar dalam menurunkan risiko infark miokard berulang dibandingkan pendahulunya yaitu bare-metal stent (BMS) dan salah satu aspek yang dikembangkan adalah material rangka. Penelitian menunjukkan bahwa antara logam stainless steel dan non-stainless steel memiliki pengaruh yang berbeda terhadap luaran klinis pasien yaitu kejadian KKM (kejadian kardiovaskular mayor) dan trombosis stent. Akan tetapi, sebagian besar penelitian dilakukan dengan follow up 1-3 tahun sementara kejadian very late stent thrombosis (VLST) yang terjadi pada DES dapat timbul sampai lima tahun. Oleh karena itu, penelitian ini dilakukan untuk mengetahui perbedaan luaran klinis dalam kurun waktu lima tahun pada pasien yang menjalani IKPP dengan platform DES stainless steel dan non stainless steel. Metode Penelitian ini merupakan penelitian analitik dengan pendekatan kuantitatif yang bertujuan untuk mengetahui pengaruh jenis logam yang digunakan pada stent, yaitu stainless steel dan ¬non-stainless steel, dengan angka kejadian KKM dan trombosis stent pada pasien yang menjalani IKPP dengan follow-up lima tahun setelah prosedur dilaksanakan. Hasil dari data tersebut akan dilakukan analisis bivariat antara variabel bebas dan variabel terikat serta akan dilakukan analisis multivariat dengan faktor-faktor determinan lain. Hasil Pada pengamatan 5 tahun, Angka kejadian luaran klinis primer dan sekunder menunjukkan tren lebih tinggi pada kelompok stainless steel dibandingkan non-stainless steel walaupun nilai p menunjukkan tidak terdapat perbedaan yang bermakna pada kedua kelompok (KKM: 47,1% vs 41,2%, p 0,511; Trombosis Stent: 11,8% vs 11,1%, p 0,780). Kesimpulan Pada pengamatan 5 tahun, tidak terdapat perbedaan bermakna pada luaran klinis primer dan sekunder pasien yang menjalani IKPP menggunakan stainless steel dibandingkan non-stainless steel. ......Introduction Primary coronary percutaneous intervention (CCI) is a management scheme that aims to restore blood supply to the heart in myocardial infarction patients with symptom onset under 12 hours and severe cardiogenic shock and patients with contraindications to fibrinolytic therapy.1 Currently, drug-eluting stents (DES) are the recommended stent type because they have greater benefits in reducing the risk of recurrent myocardial infarction compared to their predecessor, bare-metal stents (BMS) and one aspect that has been developed is the frame material. Studies have shown that stainless steel and non- stainless steel have different effects on patient clinical outcomes such as MACE (major adverse cardiovascular event) and stent thrombosis. However, most studies were conducted with a follow-up of 1-3 years while the incidence of very late stent thrombosis (VLST) that occurs in DES can occur up to five years. Therefore, this study was conducted to determine the difference in clinical outcomes within five years in patients undergoing IKPP with stainless steel and non-stainless steel DES platforms. Method This study is an analytic study with a quantitative approach that aims to determine the effect of the type of metal used in stents, namely stainless steel and non-stainless steel, with the incidence of MACE and stent thrombosis in patients undergoing IKPP with a five-year follow-up after the procedure. The results of the data will be subjected to bivariate analysis between the independent variable and the dependent variable and multivariate analysis will be conducted with other determinant factors. Results At 5-year follow-up, the incidence of primary and secondary clinical outcomes showed a higher trend in the stainless steel group compared to the non-stainless steel group although the p value showed no significant difference between the two groups (MACE: 47.1% vs 41.2%, p 0.511; Stent Thrombosis: 11.8% vs 11.1%, p 0.780). Conclusion At 5-year follow-up, there was no significant difference in the primary and secondary clinical outcomes of patients who underwent IKPP using stainless steel versus non- stainless steel.